Editorial issue 301

Let me start this 301st editorial by  a recent paper from the J Clin Invest. The group of Veronique Wittko-Sarsat from Necker Hospital (Paris) indeed publishes an elegant study: "Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis".
The next 2 papers were very recently published in NDT. S Bhandari et al publish a study protocol "Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial". This trial is the logical step following an observational study in NDT from the same group some years ago. Next, MD Witham MD and EJ Lamb EJ discuss in a review an important topic "Should chronic metabolic acidosis be treated in older people with chronic kidney disease?"
Finally, 2 papers from Kidney Int. U. Selamet reports a posthoc analysis of the MDRD study: "Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study".
And CG Couchoud et al report the "Development of a risk stratification algorithm to improve patient-centered care and decision making for incident elderly patients with end-stage renal disease".

CME lectures   
The 3 CME lectures for this issue were presented in London at the recent ERA-EDTA  Congress. They deal with CV aspects of CKD. Prof. Gunnar Heine (Homburg, Germany). discusses "FGF-23: innocent bystander or causative factor in CKD-associated CV disease?". Next, Prof. Andrzej Wiecek (Katowice, Poland) elegantly reviews the "Role of adipokines in cardiovascular complications in CKD patients- new evidence".
And Prof Carmine Zoccali (Reggio Calabria) provides an overview on "FGF23 and ADMA interaction in CKD progression".

Enjoy NDT-Edu!

Prof. Michel Jadoul
Editor-in-Chief NDT-Educational